Asset Details
Do you wish to reserve the book?
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
Do you wish to request the book?
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
2017
Overview
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. In the metastatic setting, the majority of patients respond to initial therapies but eventually develop resistance and progress. In this study, we test the hypothesis that priming with epigenetic therapy sensitizes CRC cell lines, which were previously resistant to subsequent chemotherapeutic agents. When multiple CRC cell lines are first exposed to 500 nM of the DNA demethylating agent, 5-aza-cytidine (AZA) in-vitro, and the cells then established as in-vivo xenografts in untreated NOD-SCID mice; there is an enhanced response to cytotoxic chemotherapy with agents commonly used in CRC treatment. For irinotecan (IRI), growth diminished by 16-62 fold as assessed, by both proliferation (IC50) and anchorage independent cell growth soft agar assays. Treatment of resistant HCT116 cell line along with in-vivo, for CRC line xenografts, AZA plus IRI again exhibits this synergistic response with significant improvement in survival and tumor regression in the mice. Genome-wide expression correlates changes in pathways for cell adhesion and DNA repair with the above responses. A Phase 1/2 clinical trial testing this concept is already underway testing the clinical efficacy of this concept in IRI resistant, metastatic CRC (NCT01896856).
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Animals
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Agents - toxicity
/ ATP-Binding Cassette Transporters - genetics
/ ATP-Binding Cassette Transporters - metabolism
/ Azacitidine - therapeutic use
/ Camptothecin - analogs & derivatives
/ Camptothecin - therapeutic use
/ Cancer
/ Cell Adhesion - drug effects
/ Cell Proliferation - drug effects
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - pathology
/ DNA
/ DNA Methylation - drug effects
/ Gene Expression - drug effects
/ Genomes
/ Humans
/ Long Interspersed Nucleotide Elements - genetics
/ Medicine
/ Medicine and Health Sciences
/ Mice
/ Oncology
/ Priming
/ Research and Analysis Methods
/ Studies
/ Surgery
/ Tumors
